KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Total Liabilities (2016 - 2025)

TherapeuticsMD (TXMD) has disclosed Total Liabilities for 16 consecutive years, with $11.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Liabilities fell 9.88% year-over-year to $11.2 million, compared with a TTM value of $11.2 million through Sep 2025, down 9.88%, and an annual FY2024 reading of $11.5 million, down 18.33% over the prior year.
  • Total Liabilities was $11.2 million for Q3 2025 at TherapeuticsMD, roughly flat from $11.2 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $274.0 million in Q1 2022 and bottomed at -$32.0 million in Q1 2023.
  • Average Total Liabilities over 5 years is $96.5 million, with a median of $22.4 million recorded in 2023.
  • The sharpest move saw Total Liabilities crashed 111.69% in 2023, then surged 141.92% in 2024.
  • Year by year, Total Liabilities stood at $263.1 million in 2021, then crashed by 78.98% to $55.3 million in 2022, then tumbled by 74.65% to $14.0 million in 2023, then fell by 18.33% to $11.5 million in 2024, then decreased by 1.96% to $11.2 million in 2025.
  • Business Quant data shows Total Liabilities for TXMD at $11.2 million in Q3 2025, $11.2 million in Q2 2025, and $11.5 million in Q1 2025.